| Pasha Darvishi, MD | |
|
8700 Sudley Rd, Manassas, VA 20110-4418 | |
| (703) 369-8000 | |
| Not Available |
| Full Name | Pasha Darvishi |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 8700 Sudley Rd, Manassas, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689037970 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 0101275803 (Virginia) | Primary |
| Entity Name | University Of Virginia Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720233596 PECOS PAC ID: 2567479405 Enrollment ID: O20090421000339 |
News Archive
The Neurosurgery Research and Education Foundation (NREF), which reached an agreement with Codman & Shurtleff, Inc. (Codman) in December 2009 to provide funding to the NREF in support of the Foundation's new post-residency, clinical fellowship grant program, is pleased to announce that the following programs have been awarded fellowship funding for 2010-2011: Baylor College of Medicine (pediatric neurosurgery), Brigham & Women's Hospital (general neurosurgery),
Pressure BioSciences, Inc., a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT")-based instruments and consumables to the worldwide life sciences industry, today announced the receipt of the first purchase order for its new Barozyme HT48 High-throughput System.
New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.
The individual mix of microorganisms in the human gastrointestinal tract provides vital clues as to how any future incidence of type 2 diabetes can be predicted, prevented and treated. This is demonstrated in a population study led from the University of Gothenburg.
Celldex Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.
› Verified 1 days ago
| Entity Name | Uva Community Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023483567 PECOS PAC ID: 4688587967 Enrollment ID: O20110311000151 |
News Archive
The Neurosurgery Research and Education Foundation (NREF), which reached an agreement with Codman & Shurtleff, Inc. (Codman) in December 2009 to provide funding to the NREF in support of the Foundation's new post-residency, clinical fellowship grant program, is pleased to announce that the following programs have been awarded fellowship funding for 2010-2011: Baylor College of Medicine (pediatric neurosurgery), Brigham & Women's Hospital (general neurosurgery),
Pressure BioSciences, Inc., a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT")-based instruments and consumables to the worldwide life sciences industry, today announced the receipt of the first purchase order for its new Barozyme HT48 High-throughput System.
New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.
The individual mix of microorganisms in the human gastrointestinal tract provides vital clues as to how any future incidence of type 2 diabetes can be predicted, prevented and treated. This is demonstrated in a population study led from the University of Gothenburg.
Celldex Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pasha Darvishi, MD Po Box 748613, Atlanta, GA 30384-8613 Ph: () - | Pasha Darvishi, MD 8700 Sudley Rd, Manassas, VA 20110-4418 Ph: (703) 369-8000 |
News Archive
The Neurosurgery Research and Education Foundation (NREF), which reached an agreement with Codman & Shurtleff, Inc. (Codman) in December 2009 to provide funding to the NREF in support of the Foundation's new post-residency, clinical fellowship grant program, is pleased to announce that the following programs have been awarded fellowship funding for 2010-2011: Baylor College of Medicine (pediatric neurosurgery), Brigham & Women's Hospital (general neurosurgery),
Pressure BioSciences, Inc., a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT")-based instruments and consumables to the worldwide life sciences industry, today announced the receipt of the first purchase order for its new Barozyme HT48 High-throughput System.
New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.
The individual mix of microorganisms in the human gastrointestinal tract provides vital clues as to how any future incidence of type 2 diabetes can be predicted, prevented and treated. This is demonstrated in a population study led from the University of Gothenburg.
Celldex Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.
› Verified 1 days ago
Dr. Liisa L Laakso, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 8700 Sudley Rd, Manassas, VA 20110 Phone: 703-369-8073 Fax: 703-369-8032 | |
Michael B. Robins, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 8629 Sudley Rd, Suite 102, Manassas, VA 20110 Phone: 703-369-8341 Fax: 703-369-8423 | |
Dr. Brian T Fogarty, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 8700 Sudley Rd, Manassas, VA 20110 Phone: 703-369-8073 Fax: 703-369-8032 | |
Dr. Peter J Ahn, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 8700 Sudley Rd, Manassas, VA 20110 Phone: 703-369-8073 Fax: 703-369-8032 | |
Dr. Dalton R Daniel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 8700 Sudley Rd, Manassas, VA 20110 Phone: 703-369-8073 | |
Philip N. Massey, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 8629 Sudley Rd, Suite 102, Manassas, VA 20110 Phone: 703-361-3030 Fax: 703-361-2687 | |
Namik Erdag, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 8629 Sudley Rd, Suite 102, Manassas, VA 20110 Phone: 703-361-3030 |